Azitra says press release available on ATR-COSF ex vivo repeat-dose, anti-wrinkle results

Azitra Inc.

Azitra Inc.

AZTR

0.00
  • Azitra posted a press release on July 15, 2026, reporting new ex vivo repeat-dose distribution results for its ATR-COSF cosmetic program.
  • Data showed increased rHDfilaggrin penetration into the stratum granulosum versus prior single-dose work.
  • A separate ex vivo study showed dose-dependent elasticity gains, up to 4.4-fold, supporting an anti-wrinkle positioning ahead of a planned human study.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Azitra Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY05259) on July 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.